Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Hyzaar blood pressure reduction is 50% greater than Cozaar alone; combo approved April 28.

Executive Summary

MERCK HYZAAR BLOOD PRESSURE REDUCTION IS 5.5/3.5 mmHg BETTER THAN COZAAR at the starting dose of the combination product, according to labeling approved by FDA April 28. The combination offers the potential for a 50% increase in blood pressure reduction compared to losartan alone, Merck said. The approval comes exactly two weeks after the agency's April 14 approval of Merck's Cozaar (losartan potassium tablets). Hyzaar is a combination of Cozaar and low-dose hydrochlorothiazide indicated for treatment of hypertension. Merck filed the Hyzaar NDA (20-387) on Dec. 10, 1993.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel